l e t t e r s Psoriatic arthritis (PsA) is an inflammatory joint disease that is distinct from other chronic arthritides and which is frequently accompanied by psoriasis vulgaris (PsV) and seronegativity for rheumatoid factor. We conducted a genome-wide association study in 609 German individuals with PsA (cases) and 990 controls with replication in 6 European cohorts including a total of 5,488 individuals. We replicated PsA associations at HLA-C and IL12B and identified a new association at TRAF3IP2 (rs13190932, P = 8.56 × 10 −17 ). TRAF3IP2 was also associated with PsV in a German cohort including 2,040 individuals (rs13190932, P = 1.95 × 10 −3 ). Sequencing of the exons of TRAF3IP2 identified a coding variant (p.Asp10Asn, rs33980500) as the most significantly associated SNP (P = 1.13 × 10 −20 , odds ratio = 1.95). Functional assays showed reduced binding of this TRAF3IP2 variant to TRAF6, suggesting altered modulation of immunoregulatory signals through altered TRAF interactions as a new and shared pathway for PsA and PsV.
PsV is a common chronic inflammatory disease that affects the skin and is mediated by T cells. The more than coincidental occurrence of PsV in conjunction with inflammatory arthritis in up to 15% of individuals with PsV 1 led to the recognition of PsA as a separate disease. In order to distinguish PsA from other forms of inflammatory arthritis, consensus classification criteria (as defined by the Classification of Psoriatic Arthritis study group (CASPAR)) were recently established 2 .
A strong genetic component for PsA has been suggested by several studies, indicated, for example, by a relative risk of up to 40 for firstdegree relatives and a relative risk of 12 for second-degree relatives of PsA cases 3 , which suggests that PsA has a stronger heritability than PsV 4 . However, knowledge of the genetic components contributing to PsV is more advanced than that for PsA. Common established susceptibility factors for PsV and PsA include an HLA-C risk allele 5, 6 as well as variants in or near IL23R and IL12B (refs. 7,8) , whereas a frequent deletion within the epidermal differentiation complex contributes to skin involvement (in PsV) 9 but not to joint involvement (in PsA) 10 .
In order to identify additional susceptibility genes for PsA, we performed a genome-wide association study (GWAS) in 609 German PsA cases and 990 control individuals using the Affymetrix Genome-Wide Human SNP Array 6.0. After genotyping, stringent quality-control filtering and imputation of SNPs in linkage disequilibrium (LD), 1,585,307 SNPs in 572 cases and 888 controls were used in the analysis. P values corrected for inflation showed a final genomic-control inflation factor (λ GC ) of 1.055 (Online Methods). This post-qualitycontrol sample size had 80% power to detect an odds ratio (OR) of 1.63 for an allele frequency of 0.5 or an OR of 2.20 for an allele frequency of 0.1 at genome-wide significance level, taking into account the final λ GC . A quantile-quantile plot of the initial GWAS data showed substantial deviation from the expected distribution of genome-wide P values for an unusually high number of SNPs ( Supplementary Fig. 1a ), which was considerably reduced upon removal of SNPs within the major histocompatibility complex region ( Supplementary Fig. 1b ).
l e t t e r s
We identified a genome-wide significant association (defined as P < 5 × 10 −8 ) at two previously established susceptibility loci ( Fig. 1 and Table 1 ): rs13191343, upstream of HLA-C (P = 2.25 × 10 −20 ), and rs12188300, upstream of IL12B (P = 2.40 × 10 −8 ). At a third locus, two intronic variants (rs13196377, P = 9.36 × 10 −7 and rs13210247, P = 5.76 × 10 −7 ) and one coding variant (rs13190932, P = 9.19 × 10 −7 ) of TRAF3IP2, which had not previously reported to be involved in PsA susceptibility, had a significant association with PsA. In the replication phase, a genome-wide significant association (rs13190932, Cochran-Mantel-Haenszel P = 4.53 × 10 −10 ) was also observed at this locus.
In order to confirm association at these loci, validation groups comprising a total of 1,761 cases and 3,727 control subjects of European descent from the Psoriatic Arthritis Genetics in Europe (PAGE) Consortium were genotyped for the most significant SNPs at HLA-C and IL12B as well as for the three most significantly associated variants at TRAF3IP2. The most significant association was observed in the HLA region; rs13191343, located 1.2 kb upstream of HLA-C, had the strongest evidence for association both in the initial GWAS and in the validation study ( Table 1 and Fig. 1b ). Taking into account the differing European backgrounds of our study groups, we used the Cochran-Mantel-Haenszel test in order to determine the level of association in the GWAS dataset, the validation groups and the combined dataset. rs12191877 has previously been described as the most significantly associated PsV variant in a GWAS of individuals of European origin 11 and is located further upstream (13 kb) of HLA-C.
LD analysis revealed strong LD of this SNP with rs13191343 (r 2 = 0.95) in German PsA cases, suggesting that these two signals are not independent. Similarly, we observed strong LD (r 2 = 0.95) of this SNP with the most significantly associated variant, rs10484554, described in a combined study for PsA and PsV 12 , which is even further upstream of HLA-C (Supplementary Table 4 ).
The association of PsA with rs12188300 at IL12B ( Table 1 and Supplementary Fig. 2c ) was replicated in the validation groups. This is a known PsV susceptibility locus, and previous studies have identified two SNPs that contribute to risk of PsV independently of each other (rs3212227 and rs6887695) 7 . Association of both variants with PsA has also been reported previously 8, 13 . However, a so-far unreported third SNP, rs12188300, located 72 kb upstream of the gene, showed the most significant association in our PsA GWAS ( Table 1 and Supplementary Table 1 ). This variant may represent an independent risk factor, as its LD with rs2082412 was negligible (r 2 = 0.02). The variant is located in a moderately conserved sequence that might modify expression of IL12B, but this hypothesis will require experimental confirmation.
Association at the TRAF3IP2 locus was also replicated in the independent validation groups ( Table 1 ). TRAF3IP2 has not previously been implicated in any immunological disease. Two intronic variants (rs13210247 and rs13196377) and one coding variant (rs13190932, p.Arg74Trp) were associated at a combined P = 5.56 × 10 17 and had ORs of up to 1.8 ( Table 1) . Comparative analyses of the three SNPs in Recombination rate (cM/Mb) l e t t e r s German individuals with either PsA or in an independent group with PsV suggested a less significant association for TRAF3IP2 with PsV (rs33980500, P = 1.35 × 10 −4 ) than with PsA and suggested an even less significant association (P = 0.0026) when compared to a subset of 788 individuals with PsV with a disease duration of more than 15 years, who are unlikely to develop PsA (Supplementary Table 2 ). The 95% CIs for the ORs observed for PsA and PsV overlapped, so it remains possible that the different observed effect sizes between these psoriasis phenotypes are due to chance and not a primary association with PsA. Notably, researchers from another GWAS of psoriasis published in this issue 14 observed a lower OR for a highly correlated SNP mapping to this locus (rs240993, P = 8.71 × 10 −13 , OR = 1.36, 95% CI 1.25-1.48) 14 .
Further detailed analyses are necessary to determine whether this locus is differentially associated with PsA and PsV. All three variants tag a haplotype that is present in between 2% and 10% of Europeans, as well as in individuals of African and Asian (Han Chinese and Japanese) descent. Sequencing of all exons of TRAF3IP2 in 24 PsA cases identified an additional coding variant (rs33980500, p.Asp10Asn). Genotyping of this SNP in the entire PsA cohort showed a more significant association with PsA (combined P = 1.13 × 10 −20 , OR = 1.95) and an association to PsV (P = 1.35 × 10 −4 , OR = 1.52). rs33980500 (p.Asp10Asn), but not rs13190932 (p.Arg74Trp), was present also on an additional rarer haplotype (frequency in cases = 3.4%) associated with PsA and PsV ( Fig. 2a and Supplementary Table 3 ), suggesting this as the causative variant. Comparison with sequences of chimpanzee and other mammals as well as with Neanderthal sequences indicates that the non-risk allele (D) is the ancestral allele. Both coding variants lead to an amino acid substitution in the N-terminal TRAF binding site. TRAF3IP2 encodes ACT1, a signaling adaptor involved in the regulation of adaptive immunity. Studies of TRAF3IP2-deficient mice suggest that Act1 is a negative regulator of humoral immunity through its inhibitory effect on CD40-and BAFFR-mediated signaling 15, 16 .
This B-cell-specific negative regulatory impact on the CD40 pathway by TRAF3IP2 as a newly proposed PsA-associated gene is consistent with the lack of an autoantibody signature in PsA, as is usually observed in rheumatoid arthritis. On the other hand, ACT1 concomitantly operates as a positive signaling adaptor in IL-17-mediated cellular immune responses 15, 16 . IL-17 is a dominant 'signature' cytokine of TH-17 cells and upregulates neutrophil-mobilizing cytokines, chemokines and tissue-degrading matrix metalloproteases 17 . IL-17-dependent receptor ligation induces ACT1 recruitment to the cytoplasmic tail of the IL-17R 15 . This in turn allows the incorporation of the TNF receptor-associated factors (TRAF) TRAF3 and TRAF6 into the signaling complex and the subsequent downstream activation of the MAPK and NF-κB pathway 15, 16, 18 . Accordingly, ACT1 is not only involved in pathways balancing humoral and cellular immunity, but it also represents a chief link between IL-17-mediated adaptive immune responses and NF-κB as the master regulator of innate immunity 19 controlling the inducible transcription of various pro-inflammatory cytokines. Notably, recent GWAS for PsV and rheumatoid arthritis have identified different genes involved in NF-κB regulation as influencing susceptibility: TNFAIP3 influences PsV and rheumatoid arthritis 11, 20 , TNIP1 influences PsV 11 and PRKCQ and TNFRSF14 influence rheumatoid arthritis susceptibility 21, 22 . However, none of these genes was significantly associated with PsA in our study.
Given the position of the two coding TRAF3IP2-associated SNPs, we hypothesized that the associated alleles may affect interaction with TRAF3 and/or TRAF6. We therefore investigated binding of the alleles using a mammalian two-hybrid dual-luciferase reporter assay 23 (Fig. 2b) . In our investigations, we detected a strong and specific firefly luciferase reporter induction upon the interaction between the cotransfected TRAF6-bait and wildtype TRAF3IP2-prey constructs (up to 15-40-fold greater as compared to negative controls; Fig. 2b) . Because the bait samples containing TRAF3 instead of TRAF6 remained negative with all cotransfected TRAF3IP2 prey variants (data not shown), which is in agreement with earlier mammalian two-hybrid studies 23 , we focused our further functional analysis on the interaction between TRAF6 and wild-type as well as mutant TRAF3IP2. The introduction of the N-coding risk allele of rs33980500 (p.Asp10Asn) in the amino-terminal domain of ACT1 resulted in a nearly complete loss of ability to interact with TRAF6, as indicated by luciferase reporter activity in the range of the negative control (Fig. 2b) . By contrast, the PsA-associated TRAF3IP2 allele coding for tryptophan at rs13190932 l e t t e r s (p.Arg74Trp) did not cause any detectable change of TRAF6 binding, as indicated by luminescence signals not significantly different from those determined for TRAF6 interaction with wildtype TRAF3IP2. When both PsA risk alleles (p.Asp10Asn and p.Arg74Trp) were present in the same TRAF3IP2 construct, the negative effect of the p.Asp10Asn alteration on TRAF6 interaction was dominant (Fig. 2b) .
One-way analysis of variance showed that differences of the mean normalized luciferase responses were highly significant (P = 3.17 × 10 −11 for the interaction with TRAF6). The p.Asp10Asn alteration of ACT1 identified as critical for TRAF6 interaction was also present on both risk-conferring haplotypes of TRAF3IP2 ( Fig. 2a and Supplementary  Table 3 ). Accordingly, our results suggest that p.Asp10Asn may modulate downstream signals of different crucial immunoreceptors through altered TRAF interactions. This may ultimately lead to a shift in balance between adaptive B-and T-cell responses and innate immunity into an arthritogenic disequilibrium. This functional data, however, should be viewed as preliminary and in need of further confirmation. The delineation of the involved pathways and how they predispose to PsA will require further functional studies.
In summary, our study provides new insights into the genetic factors underlying PsA, highlights a new susceptibility gene and identifies a TRAF3IP2 coding variant that may affect binding of interacting proteins. Likely, many additional genetic variants with weaker effect sizes are also involved in PsA susceptibility, but our study is underpowered to detect them. Further studies using larger cohorts, metaanalyses and studies on endophenotypes will be required to identify these genetic variants.
URLs. PLINK (vs. 1.07), http://pngu.mgh.harvard.edu/purcell/plink/.
METhodS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. Accession codes are deposited in RefSeq under the accession code NM_147686.
Note: Supplementary information is available on the Nature Genetics website.
oNLINE METhodS
Study groups. The cases and controls consisted of a variety of different collections from Europe. Detailed clinical data is provided in the Supplementary Note. The studies were approved by the ethical committees of all participating institutions. Written informed consent was obtained from each case and control subject before enrollment. The investigations were conducted according to the Declaration of Helsinki Principles.
Genotyping and primary data analysis. Six hundred and nine German PsA samples and nine hundred ninety control samples from the population-based study of the area of Augsburg, Germany (Kooperative Gesundheitsforschung in der Region Augsburg, KORA) were genotyped on the Affymetrix Genome-Wide Human SNP Array 6.0. Genotype calling was performed with Affymetrix Power Tools version 1.10.2 using the birdseed-v2 algorithm. Samples with an overall call rate of less than 97% were excluded from further analysis, bringing the sample numbers to 603 German PsA cases and 899 cases from KORA. 718,347 SNPs had an overall call rate of at least 95% in both the German PsA group and KORA and a minor allele frequency of ≥1%.
Imputation. For imputation, SNPs passing quality control were extracted into an initial dataset. From this set, 300 randomly selected individuals (150 German PsA and 150 from KORA) were used to estimate error and recombination rates with MACH1 24 . One hundred iterations of the Markov chain were used for each chromosome using the HapMap CEU r22 dataset as a reference. After this, maximum likelihood estimation of the missing alleles was also performed with MACH1 using the full initial dataset, the calculated error and recombination rates as well as the HapMap data as input. From the MACH1 output of 2.5 million HapMap SNPs, only those imputed genotypes with at least 95% posterior probability were used; all others were marked as unknown. Finally, a filter for at least 95% of known genotypes, a minor allele frequency of at least 5% and Hardy-Weinberg equilibrium P value of ≥0.001 was applied, yielding an imputed dataset of 1,585,307 SNPs in 603 cases and 899 controls. Association analysis. Association was initially tested in a χ 2 test for independence (allelic, n = 3004) for all 1,585,307 SNPs using PLINK 25 . Genomic control 26 yielded an inflation factor of 1.219 (based on the median χ 2 value), suggesting some additional structure within the data. Principal component analysis of the unimputed dataset with EIGENSOFT 27 showed visible clustering of both cases and controls in three groups along the second principal eigenvector and removed a further 31 cases and 11 control individuals as outliers ( Supplementary Fig. 3) . Accordingly, a within-cluster Cochran-Mantel-Haenszel 2 × 2 × K (K = 3) test with the imputed data was performed with PLINK in the final dataset of 572 cases and 888 control individuals, yielding an inflation factor of λ GC = 1.177 (Supplementary Fig. 2a ). All loci with a corrected P value at least one order of magnitude below the theoretical quantile expected under the null hypothesis H 0 were then visualized in GPGraphics 28 . Three loci (at HLA-C, IL12B and TRAF3IP2) meeting the genome-wide significance level were selected for replication testing. To further reduce inflation, EIGENSOFT was used on the full, imputed data, which contained only the most likely (95% posterior probability) imputed genotypes for the final dataset of 572 cases and 888 control individuals.
Replication and quality control. For replication, genotyping of rs13191343, rs12188300, rs13196377, rs13190932 (p.Arg74Trp) and rs13210247 was performed with TaqMan technology (Applied Biosystems) using predesigned or self-designed assays in the German, Italian and Swedish study groups and with Sequenom i-Plex for the samples from the UK and Ireland. rs13191343 was genotyped with a TaqMan assay exclusively. In 548 PsA cases, genotypes of SNPs from the genome-wide association study and the replication analysis with TaqMan technology were 99.6% concordant. All SNPs had a genotyping rate of ≥95% in every study group and individual DNAs with a genotyping rate of less than 80% were excluded. Genotypes for rs13196377 in British and Irish individuals were imputed based on perfect LD with rs13190932 in HapMap data. Association in the validation dataset (K = 5, grouped by nationality) and the combination of the GWAS and replication sets (K = 8) was determined using 2 × 2 × K Cochran-Mantel-Haenszel tests. For the comparative statistics of PsA versus PsV cases, descriptive statistics using the sample odds ratio as an effect estimator was used.
Sequencing. Sequencing was performed in 8 German PsA cases homozygous for the TRAF3IP2 risk haplotype and 16 individuals homozygous for non-risk haplotypes as previously described 29 .
Analysis of rs33980500 (p.Asp10Asn) and TRAF3IP2 haplotypes. rs33980500 was genotyped by TaqMan technology in the German, Irish, Italian and UK individuals. Haplotypes within TRAF3IP2 were calculated with PHASE 29 . For combined analyses within the PsA phenotype, individuals were stratified according to nationality and a within-cluster Cochran-Mantel-Haenszel test (2 × 2 × 3) was performed.
Mammalian two-hybrid assay. A mammalian two-hybrid assay (Stratagene) was applied to analyze the interaction of wild-type and mutant protein of TRAF3IP2 with TRAF3 or TRAF6 23 . A coding segment of human TRAF3IP2, corresponding to amino acid residues 1-355, that harbors the TRAF-interacting domain 23 was PCR amplified and cloned into the pCMV-AD prey vector. TRAF3 (amino acids 51-543) and TRAF6 (amino acids 70-522) 23 were cloned accordingly into the pCMV-BD bait vector. The bait, prey (10 ng each) and the firefly luciferase reporter (250 ng) were transfected in HEK 293 cells. A renilla luciferase plasmid (pRL-TK vector, Promega) was transfected to control the transfection rate. Forty-eight hours after transfection, the luciferase expression was measured using the Dual-Luciferase Reporter Assay System (Promega). The risk alleles of rs33980500 (p.Asp10Asn) and/or of rs13190932 (p.Arg74Trp) were introduced into TRAF3IP2 to generate the PsA-associated variants for functional testing using the QuikChange site-directed mutagenesis kit (Stratagene). Prior to transfection of the bait and prey vectors, quality control was performed by DNA sequencing. An independent positive control based on the tight interaction between mouse p53 protein and viral SV40 large T antigen was performed confirming functionality of the system (relative normalized luminescence: 406,422 (95% CI 287,555-525,283) units) and the non-interacting vector combination (bait: pBD-p53 and prey: pAD-TRAF2) served as the negative control.
Analysis of variance.
Using a spreadsheet program, the normalized relative luminescence units were used to calculate the ratios of treatment to error variance of the TRAF6 dataset. P values were obtained from the cumulative F distribution with 9 degrees of freedom in the numerator and 30 degrees of freedom in the denominator, also within the same spreadsheet program.
